NCT04627831撤回2 期
Randomized Parallel Group Study Comparing the Renal Safety of CAPTISOL-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in Patients With Impaired Renal Function Undergoing Coronary Angiography
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Incidence of contrast-induced acute kidney injury (CI-AKI)
研究概览
简要总结
Randomized parallel group study comparing the renal safety of Captisol-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in patients with impaired renal function undergoing coronary angiography.
详细描述
The purpose of this trial is to demonstrate a reduction in the incidence of contrast-induced acute kidney injury (CI-AKI), also known as contrast-induced nephropathy (CIN), and the equivalence of image quality following administration of Captisol-Enabled™-Iohexol (CE-Iohexol) Injection compared to Omnipaque™(Iohexol) Injection in patients with impaired renal function undergoing invasive coronary angiography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Subjects, and site personnel evaluating the subjects, will be blinded to the contrast media administered.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged ≥18 years
- •Referred for a coronary angiography (with or without percutaneous coronary intervention) and must meet either 1 of the following criteria:
- •Estimated glomerular filtration rate (eGFR) <45 and ≥15 mL/min/1.73 m2 as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD- EPI) equation; or
- •eGFR <60 and ≥45 mL/min/1.73 m2 as determined by the CKD-EPI equation and at least 1 of the following conditions:
- •Age >75 years
- •Diabetes mellitus with glycosylated hemoglobin (HbA1c) ≤10%
- •New York Heart Association (NYHA) class II or III heart failure
- •Albuminuria with urine albumin-to-creatinine ratio (UACR) or urine protein-to- creatinine ratio (UPCR) ≥300 and ≤4000 mg/g; or
- •Anemia, with hemoglobin levels ≥8 g/dL but <12.0 g/dL in women and <13.0 g/dL in men, as defined by the World Health Organization
- •If female, must also meet any 1 of the following criteria:
- •Surgically sterile with bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy
- •Postmenopausal with amenorrhea for at least 1 year and follicle-stimulating hormone in the postmenopausal range; or
- •Is a woman of childbearing potential, non-pregnant and non-lactating at Screening, and must agree to use a protocol-recommended method of birth control or abstain from heterosexual intercourse, beginning at least 30 days prior to and until 30 days following investigational contrast agent administration
- •If a male who can father a child, must also meet all of the following criteria:
- •Willing to use a protocol-recommended method of birth control, ie, a double barrier approach (eg, condoms with spermicide) or abstain from heterosexual intercourse with women of childbearing potential, from Day 1 until at least 90 days after investigational contrast agent administration; and
- •Willing to refrain from sperm donation from Day 1 until at least 90 days after investigational contrast agent administration
- •Willing to undergo protocol-recommended blood and urine collections, physical examinations, and laboratory investigations; and
- •Willing and able to provide written informed consent
- •Exclusion criteria
- •eGFR <15 mL/min/1.73 m2
- •Reduction in eGFR by approximately 25% that is considered to be acute per the Investigator's judgment
- •Body weight >125 kg
- •Uncorrected clinically significant abnormalities of clinical laboratory assessments which, in the Investigator's opinion, will interfere with the study conduct, including but not limited to the following:
- •HbA1c >10%
- •Blood glucose >270 mg/dL
- •Hemoglobin <8 g/dL
- •Albuminuria with UACR or UPCR >4000 mg/g; or
- •Aspartate aminotransferase or alanine aminotransferase >3 x upper limit of reference range
- •Positive test for severe acute respiratory syndrome coronavirus 2 RNA at Screening;
- •Positive test for human immunodeficiency virus antibody, hepatitis B surface antigen, or hepatitis C virus RNA at Screening
- •Uncontrolled hypertension, with systolic blood pressure (BP) >180 mmHg or diastolic BP >110 mmHg at Screening, based on the average of 3 BP measurements obtained from the patient's dominant arm
- •Hypotension, that is considered to be of recent occurrence per the Investigator's judgment, and required resuscitation with intravenous fluids
- •Non-cardiac acute illness or injuries that, in the opinion of the Investigator, could put the patient at risk or obscure the interpretation of the results of the study
- •Known allergy or sensitivity to iodinated contrast agents, Captisol, or any of the excipients in the study contrast agent that cannot be adequately managed with prophylactic treatment per the Investigator's judgment and Good Clinical Practice
- •Known allergy to heparin, history of heparin-induced thrombocytopenia, or history of heparin induced thrombocytopenia with thrombosis
- •Chronic disease(s) that, in the opinion of the Investigator, could interfere with (or for which the treatment might interfere with) the conduct of the study or interpretation of the study results or would place the patient at undue risk by participating in the study, including but not limited to the following:
- •NYHA class IV or decompensated heart failure; or
- •Cirrhosis of the liver
- •Inability to receive periprocedural intravenous volume expansion
- •Received contrast media within 10 days prior to the scheduled coronary angiography
- •Unable or not willing to come off non-steroidal anti-inflammatory drugs, including ibuprofen, for at least 24 hours before the scheduled procedure
排除标准
- 未提供
研究组 & 干预措施
CE-Iohexol
Experimental
Subject is randomized to receive CE-Iohexol Injection
干预措施: CE-Iohexol (Drug)
Omnipaque™ (Iohexol)
Active Comparator
Subject is randomized to receive Omnipaque™ Iohexol Injection
干预措施: Iohexol (Drug)
结局指标
主要结局
Incidence of contrast-induced acute kidney injury (CI-AKI)
时间窗: 7 days
Evaluate the incidence of CI-AKI in patients with impaired renal function undergoing coronary angiography, from baseline to any blood draw within 7 days following intravascular administration of CE-iohexol compared with Omnipaque (iohexol).
次要结局
- Change in serum creatinine (SCr)(7 days)
- Image quality(Day 1)
- Proportion of patients exhibiting an increase in SCr(7 days)
- Change in serum cystatin C(7 days)
- Incidence of Adverse Events(30 days)
研究者
相似试验
已完成
3 期
Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)Kidney FailureNCT01595984Centre Hospitalier Universitaire, Amiens88
已完成
4 期
Study for renal outcomes with different combination therapies including Telmisartan in patients with type 2 diabetes and hypertensiotype 2 diabetes mellitusJPRN-UMIN000005865Hokkaido University Hospital105
已完成
4 期
Study of Atorvastatin Dose Dependent Reduction of ProteinuriaChronic Kidney DiseaseNCT00768638Laval University23
已完成
不适用
Bundle Evaluation in Extra Renal Epuration, Incidence of ThrombosisAdults Receiving Renal Replacement TherapyNCT01560364University Hospital, Clermont-Ferrand100
已完成
4 期
A Safety Comparison of Iopromide and Iodixanol in Renal Impaired PatientsKidney Failure, ChronicNCT00926562Chinese PLA General Hospital592